Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid (TA) vs Combined Oral Contraceptive (COCP) Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Menstruating females with menorrhagia or menometrorrhagia referred to hematology or gynecology clinics at Texas Childrens Hospital. Menorrhagia is defined as regular periods with heavy menstrual bleeding with a PBAC score greater than 100; menometrorrhagia is heavy vaginal bleeding occurring at irregular intervals.~2. PBAC Score greater than 100 for 2 consecutive cycles~3. Pelvic ultrasound that excludes pelvic pathology that can cause menorrhagia within 12 months prior to study participation.~4. Normal external genitalia examination within 6 months prior to study participation.~5. Normal thyroid stimulating hormone (TSH) in the last 6 months prior to study participation.~6. Negative urine or serum pregnancy test within 4 weeks prior to study participation.~Exclusion Criteria:~1. Presence of intra uterine device.~2. Presence of a diagnosed bleeding disorder based on the standard work-up including complete blood count (CBC), prothrombin time, partial thromboplastin time, fibrinogen, von Willebrand panel and platelet function analysis (PFA-100) or platelet aggregation.~3. Intake of medications with increased risk of bleeding~4. Taking herbal products.~5. Sexually active status.~6. Body weight less than 40 kg.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Group A-Oral tranexamic acid (Type: ACTIVE_COMPARATOR): Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
- Group B-Combined oral contraceptive pills (Type: ACTIVE_COMPARATOR): Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.

Based on this trial design, predict the completion outcome and termination type (if applicable).